PRP vs. PDGF+: One Is Injected. One Should Never Be.

Patients ask me about these two as though they’re competing versions of the same treatment — as if PDGF+ were PRP with an upgrade. That framing is everywhere online, and it’s wrong in a way that matters.

PRP comes out of your blood drawn from your veins. PDGF+ comes out of a vial and is manufactured in yeast. One can be used either topically or injected; the other is approved for topical use only.

We use both. PRP is included at no charge with every microneedling treatment here; PDGF+ is a paid add-on. So I have a financial interest in the more expensive one, which is worth knowing before I tell you where I think each belongs.

What is PRP, actually?

Your own blood, drawn, spun in a centrifuge to concentrate the platelets, and re-injected or applied. The same preparation is used for PRP joint injections, though this article is about hair and skin. Platelets carry a mixture of growth factors — PDGF among them, along with VEGF, EGF and others — that the body deploys during wound healing.

Because it comes from you, there is nothing foreign to react to. That’s its central advantage, and it’s why we use it as the gliding agent during microneedling and as the post-procedure mask. In reactive skin, “nothing in it that isn’t already yours” is worth a great deal.

Its central disadvantage is the flip side: what you get depends on your blood that day. Platelet concentration varies between people and within the same person over time.

Does PRP actually work for hair?

Yes, but with several caveats worth being mentioned.

The largest current synthesis — 43 randomised controlled trials covering 1,877 participants, published in Dermatology and Therapy — found that activated PRP increased hair density and reduced recurrence compared with placebo, while non-activated PRP was associated with more frequent adverse effects. That distinction between preparation methods matters and almost nobody mentions it.

A 2024 meta-analysis in Anais Brasileiros de Dermatologia pooling 14 studies and 431 patients reached a similar conclusion, and then said the quiet part: the underlying studies are highly heterogeneous and show publication bias, and better randomised trials are needed.

There’s a further detail worth having. A 2023 meta-analysis of nine trials found PRP significantly increased hair density versus placebo at three and six months — but hair count and hair diameter, while improved from each patient’s own baseline, were not significantly better than placebo.

Fact vs. Fad: “PRP regrows hair” is too strong. “PRP increases hair density in androgenetic alopecia, in studies of variable quality, with the effect strongest for density rather than for the thickness of individual hairs” is what the evidence supports. It works on follicles that are miniaturised but still alive. It will not bring back a follicle that has been gone for a decade, and I’d rather you hear that before you pay than after.

So what is PDGF+?

A topical serum. Four ingredients: water, sodium acetate, hyaluronic acid, and sh-polypeptide-59 dimer — which is the cosmetic-ingredient name for recombinant human PDGF-BB.

“Recombinant” means it’s produced by genetically modified yeast engineered to make that specific protein, then purified. It doesn’t come from anyone’s blood. Every vial is identical, sterile and standardised, which is a genuine advantage over PRP’s batch-to-batch variability, and it requires no blood draw.

We apply it immediately after microneedling or laser, while the microchannels are still open, and it can be used the same way as a post-Morpheus8 application. For scalp work, it goes on topically alongside microneedling.

Then why shouldn’t it be injected?

Because the manufacturer says so. Unfortunately, I have seen clinic pages advertising it as an injectable anyway.

Ariessence’s own materials state that the product is intended for topical cosmetic use only. That is not a technicality — it’s the regulatory category the product was made, tested and released under. A cosmetic manufactured for topical application has not been through the manufacturing controls, sterility assurance and safety testing that an injectable drug product requires, regardless of how pure the protein inside it is.

I’ve come across practice websites describing this product being injected — into the under-eye area, in one case. That is off-label use of a cosmetic, in a plane where a foreign protein and a non-injectable hyaluronic acid formulation now sit, with no published safety data for that route. There is a real difference between “sterile” and “formulated, tested and approved for injection into human tissue.”

For hair specifically, this is the cleanest way to hold the two apart in your head: PRP is injected into the scalp. PDGF+ is not. We deliver scalp PRP with a mesotherapy injector for consistent depth and spacing. PDGF+ goes on top of skin whose barrier we have deliberately opened.

If someone offers to inject PDGF+ into your face, ask them to show you where the manufacturer says that’s an approved route.

What about the “FDA-approved growth factor” claim?

This one deserves a careful read, because the phrasing is doing real work.

You’ll see PDGF+ described as containing the only FDA-approved growth factor in aesthetics. What’s true: recombinant PDGF is the active ingredient in four FDA-approved medical products — Regranex, GEM 21S, Augment and Augment Injectable — used in diabetic foot ulcers, periodontal defects and bone grafting, with a long clinical track record.

What’s also true, and stated in the manufacturer’s own footnotes: those approvals rest on each product’s own formulation and its own trials, conducted independently of this cosmetic, for indications unrelated to cosmetic use. Their own comparison page says the FDA approval of PDGF applies only to certain medical products and indications unrelated to cosmetic use, and that Ariessence is intended for topical cosmetic use only.

So the molecule has an FDA pedigree. The cosmetic does not. That’s not fraud — the disclaimers are right there, and I’d rather credit a company that publishes them than pretend otherwise — but the headline claim and the footnote say noticeably different things, and most patients only ever encounter the headline.

Is PDGF safe?

Here’s a story I think is worth telling properly, because it cuts against my own argument and it’s a good illustration of how evidence is supposed to work.

In 2008 the FDA placed a boxed warning on Regranex — the topical PDGF gel — after a retrospective claims-database study found a roughly fivefold increase in cancer mortality among patients who used three or more tubes. That’s about as alarming as a safety signal gets.

Then it was investigated properly. Extended follow-up on that same cohort found no elevated cancer mortality overall, and a Veterans Affairs analysis comparing 6,429 treated patients against 6,429 matched controls across eleven years found no increased cancer incidence or cancer mortality. In November 2018 the FDA approved removal of the boxed warning.

If I were building a case against this product, I’d quote the 2008 warning and stop. That would be dishonest by omission — the same failure mode as citing a conference abstract as though it were a peer-reviewed trial. The signal was raised, tested at scale, and retracted. That is the system working.

So which should you choose?

For hair: PRP, injected, in a series — that’s where the randomised evidence sits, and it’s what we do for hair restoration.

For post-procedure skin recovery: either works. PRP is included with your microneedling and has nothing foreign in it. PDGF+ costs more, requires no blood draw, and is identical vial to vial. If you’re needle-averse or have difficult veins, that’s a real reason to prefer it.

For injection into skin: PRP only. Not PDGF+, and not because I doubt the molecule — because a topical cosmetic has not been tested for that route and there’s no good reason to be the person it gets tested on.

References

Platelet-rich plasma in the management of alopecia: a systematic review and meta-analysis of clinical evidence. Dermatology and Therapy. 2025. doi:10.1007/s13555-025-01542-8 (43 randomised controlled trials, n=1,877)

Kieling L, Konzen AT, Zanella RK, Valente DS. Is autologous platelet-rich plasma capable of increasing hair density in patients with androgenic alopecia? A systematic review and meta-analysis of randomized clinical trials. Anais Brasileiros de Dermatologia. 2024;99(6):847–862. doi:10.1016/j.abd.2024.01.002

Zhang X, Ji Y, Zhou M, et al. Platelet-rich plasma for androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials. Journal of Cutaneous Medicine and Surgery. 2023;27(5):504–508. doi:10.1177/12034754231191461

Ziyadeh N, Fife D, Walker AM, Wilkinson GS, Seeger JD. A matched cohort study of the risk of cancer in users of becaplermin. Advances in Skin & Wound Care. 2011;24(1):31–39. (matched cohort; extended follow-up showed no elevated cancer mortality overall)

Veterans Affairs retrospective cohort: 6,429 becaplermin users versus 6,429 matched comparators, 1998–2009, reported in REGRANEX gel prescribing information. (no increased cancer incidence or cancer mortality)

U.S. Food and Drug Administration. REGRANEX (becaplermin) gel prescribing information. Boxed warning added 2008; removed November 2018.

ariessence pure PDGF+ product information. Manufacturer materials, accessed August 2026.